ISRG — Intuitive Surgical, Inc.

Summary of ISRG Q1 2026 Earnings Call

1. Key Financial Results and Metrics

• Total Revenue: Increased by 23% to $2.77 billion.
• Recurring Revenue: Grew by 23% to $2.4 billion, representing 86% of total revenue.
• Total Procedures: Grew by 17%, with da Vinci procedures up 16% (847,000) and Ion procedures up 39% (43,000).
• Non-GAAP Operating Margin: Strong at 39%.
• Non-GAAP Net Income: Increased to $901 million ($2.50 per share) from $662 million ($1.81 per share) year-over-year.
• GAAP Net Income: $822 million ($2.28 per share), up from $698 million ($1.92 per share) year-over-year.
• Cash and Investments: Ended the quarter at $8 billion, down from $9 billion due to stock repurchases and acquisitions.

2. Strategic Updates and Business Highlights

• Procedure Growth: Notable growth in U.S. da Vinci procedures (14%) and strong international growth (19%).
• Product Launches: Continued expansion of da Vinci 5, Ion, and Single Port (SP) platforms. SP procedures grew 68% year-over-year.
• Clinical Advancements: Received FDA clearance for additional uses of Force Feedback instruments, expected to enhance surgical outcomes.
• Digital Ecosystem: Investments in data and digital infrastructure are progressing, with plans for AI integration and telesurgery capabilities.
• Leadership Transition: Dr. Myriam Curet retired; Dr. Jamie Wong appointed as new Chief Medical Officer.

3. Forward Guidance and Outlook

• Da Vinci Procedure Growth: Updated forecast for 2026 to 13.5% to 15.5%, up from the previous estimate.
• Gross Profit Margin: Expected to be between 67.5% and 68.5% of revenue, reflecting improved cost management.
• Operating Expenses: Anticipated growth of 11% to 14% for the year.
• Other Income: Forecasted to be between $315 million and $335 million due to lower cash balances.

4. Bad News, Challenges, or Points of Concern

• International Market Challenges: Continued difficulties in China and Japan, with lower tender activity and competitive pricing pressures affecting growth.
• U.S. Procedure Declines: Bariatric procedures declined by approximately 10% due to increased use of GLP-1 medications.
• Cybersecurity Incident: A cyber incident in Q1 resulted in unauthorized access to customer and corporate data, though it did not significantly impact financial results.
• Market Sensitivity: Potential impacts from the expiration of ACA premium subsidies and ongoing capital pressures in Europe.

5. Notable Q&A Insights

• AI and Digital Roadmap: Emphasis on using AI to enhance surgical outcomes and operational efficiencies, with a focus on high-quality data.
• Utilization Growth: While utilization rates are improving, quantifying future growth remains challenging due to market variability.
• Competitive Landscape: Discussion on tiered pricing strategies with refurbished systems to remain competitive against new entrants.
• SP Platform Potential: SP is expected to gradually gain adoption, with ongoing evaluations of its long-term market potential.

Overall, ISRG reported a strong start to 2026 with significant revenue and procedure growth, but faces challenges in certain international markets and ongoing competitive pressures. The company remains focused on innovation and expanding its digital capabilities while navigating potential headwinds.